Patients without growing brain nodule (n=73) | Patients with growing brain nodule (n=50) | p-value | |
Age years | 64.7±10.5 | 60.4±11.4 | 0.034 |
Sex male | 49 (67.1%) | 34 (68.0%) | 1.000 |
Smoking history | |||
Never | 24 (32.9%) | 17 (34.0%) | 1.000 |
Current | 15 (20.5%) | 14 (28.0%) | 0.459 |
Ex-smoker | 34 (46.6%) | 19 (38.0%) | 0.449 |
Pack-years | 24.2±25.4 | 21.1±23.3 | 0.494 |
TNM stage of NSCLC | |||
T stage | |||
T1 | 26 (35.6%) | 11 (22.0%) | 0.156 |
T2 | 28 (38.4%) | 24 (48.0%) | 0.380 |
T3 | 13 (17.8%) | 8 (16.0%) | 0.986 |
T4 | 6 (8.2%) | 7 (14.0%) | 0.468 |
N stage | |||
N0 | 33 (45.2%) | 13 (26.0%) | 0.049 |
N1 | 9 (12.3%) | 5 (10.0%) | 0.912 |
N2 | 16 (21.9%) | 15 (30.0%) | 0.422 |
N3 | 15 (20.5%) | 17 (34.0%) | 0.144 |
Extracranial TNM stage | |||
Stage I | 20 (27.4%) | 5 (10.0%) | 0.033 |
Stage II | 13 (17.8%) | 2 (4.0%) | 0.044 |
Stage III | 21 (28.8%) | 11 (22.0%) | 0.528 |
Stage IV | 19 (26.0%) | 32 (64.0%) | <0.001 |
Treatment | |||
CCRT | 13 (17.8%) | 3 (6.0%) | 0.101 |
Systemic chemotherapy | 46 (63.0%) | 42 (84.0%) | 0.020 |
Number of brain nodules | <0.001 | ||
1 | 48 (55.2%) | 18 (21.4%) | |
2 | 29 (33.3%) | 24 (28.6%) | |
≥3 | 10 (11.5%) | 42 (50.0%) | |
Total follow-up duration months | 24.8±18.8 | 21.4±17.5 | 0.316 |
Continuous variables are expressed as mean±sd and categorical variables are expressed as the number of patients (percentage). NSCLC: nonsmall cell lung cancer; TNM: tumour, node, metastasis; CCRT: concurrent chemoradiation therapy.